Literature DB >> 27806234

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.

Vassiliki A Boussiotis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27806234      PMCID： PMC5575761          DOI： 10.1056/NEJMra1514296

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  68 in total

1.  Phosphorylation of the PTEN tail regulates protein stability and function.

Authors:  F Vazquez; S Ramaswamy; N Nakamura; W R Sellers
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

2.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine.

Authors:  T Okazaki; A Maeda; H Nishimura; T Kurosaki; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

Review 3.  The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling.

Authors:  Benjamin G Neel; Haihua Gu; Lily Pao
Journal:  Trends Biochem Sci       Date:  2003-06       Impact factor: 13.807

4.  A two-step, two-signal model for the primary activation of precursor helper T cells.

Authors:  P A Bretscher
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-05       Impact factor: 11.205

5.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

6.  Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.

Authors:  Nikolaos Patsoukis; Julia Brown; Victoria Petkova; Fang Liu; Lequn Li; Vassiliki A Boussiotis
Journal:  Sci Signal       Date:  2012-06-26       Impact factor: 8.192

7.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

8.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

Authors:  Tadashi Yokosuka; Masako Takamatsu; Wakana Kobayashi-Imanishi; Akiko Hashimoto-Tane; Miyuki Azuma; Takashi Saito
Journal:  J Exp Med       Date:  2012-05-28       Impact factor: 14.307

9.  Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.

Authors:  Brian T Fife; Kristen E Pauken; Todd N Eagar; Takashi Obu; Jenny Wu; Qizhi Tang; Miyuki Azuma; Matthew F Krummel; Jeffrey A Bluestone
Journal:  Nat Immunol       Date:  2009-09-27       Impact factor: 25.606

10.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598
View more
  379 in total

1.  An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion.

Authors:  John D Klement; Amy V Paschall; Priscilla S Redd; Mohammed L Ibrahim; Chunwan Lu; Dafeng Yang; Esteban Celis; Scott I Abrams; Keiko Ozato; Kebin Liu
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

Review 2.  Atezolizumab for the treatment of non-small cell lung cancer.

Authors:  Fernando C Santini; Charles M Rudin
Journal:  Expert Rev Clin Pharmacol       Date:  2017-07-27       Impact factor: 5.045

3.  Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.

Authors:  Xiaodong Wang; Xiaohui Yang; Chang Zhang; Yang Wang; Tianyou Cheng; Liqiang Duan; Zhou Tong; Shuguang Tan; Hangjie Zhang; Phei Er Saw; Yinmin Gu; Jinhua Wang; Yibi Zhang; Lina Shang; Yajuan Liu; Siyuan Jiang; Bingxue Yan; Rong Li; Yue Yang; Jie Yu; Yunzhao Chen; George Fu Gao; Qinong Ye; Shan Gao
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-11       Impact factor: 11.205

Review 4.  Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.

Authors:  Eleonora Molinaro; Cristina Romei; Agnese Biagini; Elena Sabini; Laura Agate; Salvatore Mazzeo; Gabriele Materazzi; Stefano Sellari-Franceschini; Alessandro Ribechini; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2017-07-14       Impact factor: 43.330

Review 5.  Transcriptional and epigenetic regulation of PD-1 expression.

Authors:  Zengde Chi; Yan Lu; Yinlong Yang; Bingqing Li; Peiyuan Lu
Journal:  Cell Mol Life Sci       Date:  2021-03-18       Impact factor: 9.261

6.  Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer.

Authors:  Masaru Katoh
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

7.  irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.

Authors:  Jean-Christophe Pignon; Opeyemi Jegede; Sachet A Shukla; David A Braun; Christine E Horak; Megan Wind-Rotolo; Yuko Ishii; Paul J Catalano; Jonian Grosha; Abdallah Flaifel; Jesse S Novak; Kathleen M Mahoney; Gordon J Freeman; Arlene H Sharpe; F Stephen Hodi; Robert J Motzer; Toni K Choueiri; Catherine J Wu; Michael B Atkins; David F McDermott; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2019-01-22       Impact factor: 12.531

8.  Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition.

Authors:  Paul T Elkington; Adrian C Bateman; Gareth J Thomas; Christian H Ottensmeier
Journal:  Am J Respir Crit Care Med       Date:  2018-12-01       Impact factor: 21.405

9.  CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer.

Authors:  Tao Wang; Quan Zhou; Han Zeng; Hongyu Zhang; Zhaopei Liu; Jialiang Shao; Zewei Wang; Ying Xiong; Jiajun Wang; Qi Bai; Yu Xia; Yiwei Wang; Li Liu; Yu Zhu; Le Xu; Bo Dai; Jianming Guo; Yuan Chang; Xiang Wang; Jiejie Xu
Journal:  Cancer Immunol Immunother       Date:  2020-05-04       Impact factor: 6.968

10.  TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.

Authors:  Tsuyoshi Hamada; Thing Rinda Soong; Yohei Masugi; Keisuke Kosumi; Jonathan A Nowak; Annacarolina da Silva; Xinmeng Jasmine Mu; Tyler S Twombly; Hideo Koh; Juhong Yang; Mingyang Song; Li Liu; Mancang Gu; Yan Shi; Katsuhiko Nosho; Teppei Morikawa; Kentaro Inamura; Sachet A Shukla; Catherine J Wu; Levi A Garraway; Xuehong Zhang; Kana Wu; Jeffrey A Meyerhardt; Andrew T Chan; Jonathan N Glickman; Scott J Rodig; Gordon J Freeman; Charles S Fuchs; Reiko Nishihara; Marios Giannakis; Shuji Ogino
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.